Corbus Pharmaceuticals Holdings Inc (CRBP)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$4.05-1.94%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Corbus Pharmaceuticals Holdings Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-1.32
Annual ending 2026-12-31
Revenue	—	2M
EPS	—	-5.435
Annual ending 2027-12-31
Revenue	—	3.6M
EPS	—	-5.514

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage cash burn and operating expenses amid clinical development	The company focuses on managing cash burn despite ongoing losses.	Broken	operating losses worsen beyond -$24.3M per quarter	Operating income: $-36.19M FY2026-Q2; GAAP. Published target: reduce or stabilize operating losses below -$24.3M per quarter. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-36,190,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: b647c286-23a6-4d2f-92cb-c79b8631761f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 supplied transcript quarters. Cash, cash equivalents, and investments were $138.2 million at March 31, 2026 and $117.9 million at June 30, 2026, while Q2 operating expenses were $36.2 million versus $19.2 million in Q2 2025. Management said the June balance was expected to fund operations into 2028, but the rising quarterly expenses and lower cash balance indicate limited progress on financial discipline as clinical spending expands. Delivery assessment Oct 24, 2026
Initiate registrational study of CRB-701 in 2L OPSCC by summer 2026	Corbus is advancing clinical trials, aiming to start a key study in summer 2026.	Intact	registrational study initiation delayed beyond 2026-Q3	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Enhance management and board to support growth	Leadership has been strengthened with new executives and board members.	Improving	key leadership departures or governance issues arise	Qualitative: 2 new execs hired, 1 new director added New CMO and CBO employment agreements signed; board expanded to seven members with new director appointment. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-5.51

$-5.08 → $-5.51 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-5.08	$2,400,000	9 / 9
2026-07-25	$-5.15	$3,600,000	7 / 9
2026-07-26	$-5.08	$2,400,000	9 / 9
2026-07-27	$-5.08	$2,400,000	9 / 9
2026-07-28	$-5.08	$2,400,000	9 / 9
2026-07-29	$-5.08	$2,400,000	9 / 9
2026-07-30	$-5.15	$3,600,000	7 / 9
2026-07-31	$-5.15	$3,600,000	7 / 9
2026-08-01	$-5.15	$3,600,000	7 / 9
2026-08-02	$-5.08	$2,400,000	9 / 9
2026-08-03	$-5.08	$2,400,000	9 / 9
2026-08-04	$-5.08	$2,400,000	9 / 9
2026-08-05	$-5.08	$2,400,000	9 / 9
2026-08-06	$-5.08	$2,400,000	9 / 9
2026-08-07	$-5.15	$3,600,000	7 / 9
2026-08-08	$-4.98	$3,085,710	9 / 7
2026-08-09	$-5.15	$3,600,000	7 / 9
2026-08-10	$-5.15	$3,600,000	7 / 9
2026-08-11	$-5.49	$2,400,000	9 / 9
2026-08-12	$-5.15	$3,600,000	7 / 9
2026-08-13	$-5.49	$2,400,000	9 / 9
2026-08-14	$-5.15	$3,600,000	7 / 9
2026-08-15	$-5.15	$3,600,000	7 / 9
2026-08-16	$-5.15	$3,600,000	7 / 9
2026-08-17	$-5.15	$3,600,000	7 / 9
2026-08-18	$-5.15	$3,600,000	7 / 9
2026-08-19	$-5.15	$3,600,000	7 / 9
2026-08-20	$-5.51	$3,600,000	7 / 9
2026-08-21	$-5.51	$3,600,000	7 / 9
2026-08-22	$-5.51	$3,600,000	7 / 9
2026-08-23	$-5.51	$3,600,000	7 / 9
2026-08-24	$-5.51	$3,600,000	7 / 9
2026-08-25	$-5.51	$3,600,000	7 / 9
2026-08-26	$-5.51	$3,600,000	7 / 9
2026-08-27	$-5.51	$3,600,000	7 / 9
2026-08-28	$-5.51	$3,600,000	7 / 9
2026-08-29	$-5.51	$3,600,000	7 / 9
2026-08-30	$-5.51	$3,600,000	7 / 9
2026-08-31	$-5.51	$3,600,000	7 / 9
2026-09-01	$-5.51	$3,600,000	7 / 9
2026-09-02	$-5.51	$3,600,000	7 / 9
2026-09-03	$-5.51	$3,600,000	7 / 9
2026-09-04	$-5.51	$3,600,000	7 / 9
2026-09-05	$-5.51	$3,600,000	7 / 9
2026-09-06	$-5.51	$3,600,000	7 / 9
2026-09-07	$-5.51	$3,600,000	7 / 9
2026-09-08	$-5.51	$3,600,000	7 / 9
2026-09-09	$-5.51	$3,600,000	7 / 9
2026-09-10	$-5.51	$3,600,000	7 / 9
2026-09-11	$-5.51	$3,600,000	7 / 9
2026-09-12	$-5.51	$3,600,000	7 / 9
2026-09-13	$-5.51	$3,600,000	7 / 9
2026-09-14	$-5.51	$3,600,000	7 / 9
2026-09-15	$-5.51	$3,600,000	7 / 9
2026-09-16	$-5.51	$3,600,000	7 / 9
2026-09-17	$-5.51	$3,600,000	7 / 9
2026-09-18	$-5.51	$3,600,000	7 / 9
2026-09-19	$-5.51	$3,600,000	7 / 9
2026-09-20	$-5.51	$3,600,000	7 / 9
2026-09-21	$-5.51	$3,600,000	7 / 9
2026-09-22	$-5.51	$3,600,000	7 / 9
2026-09-23	$-5.51	$3,600,000	7 / 9
2026-09-24	$-5.51	$3,600,000	7 / 9
2026-09-25	$-5.51	$3,600,000	7 / 9
2026-09-26	$-5.51	$3,600,000	7 / 9
2026-09-27	$-5.51	$3,600,000	7 / 9
2026-09-28	$-5.51	$3,600,000	7 / 9
2026-09-29	$-5.51	$3,600,000	7 / 9
2026-09-30	$-5.51	$3,600,000	7 / 9
2026-10-01	$-5.51	$3,600,000	7 / 9
2026-10-02	$-5.51	$3,600,000	7 / 9
2026-10-03	$-5.51	$3,600,000	7 / 9
2026-10-04	$-5.51	$3,600,000	7 / 9
2026-10-05	$-5.51	$3,600,000	7 / 9
2026-10-06	$-5.51	$3,600,000	7 / 9
2026-10-07	$-5.51	$3,600,000	7 / 9
2026-10-08	$-5.51	$3,600,000	7 / 9
2026-10-09	$-5.51	$3,600,000	7 / 9
2026-10-10	$-5.51	$3,600,000	7 / 9
2026-10-11	$-5.51	$3,600,000	7 / 9
2026-10-12	$-5.51	$3,600,000	7 / 9
2026-10-13	$-5.51	$3,600,000	7 / 9
2026-10-14	$-5.51	$3,600,000	7 / 9
2026-10-15	$-5.51	$3,600,000	7 / 9
2026-10-16	$-5.51	$3,600,000	7 / 9
2026-10-17	$-5.51	$3,600,000	7 / 9
2026-10-18	$-5.51	$3,600,000	7 / 9
2026-10-19	$-5.51	$3,600,000	7 / 9
2026-10-20	$-5.51	$3,600,000	7 / 9
2026-10-21	$-5.51	$3,600,000	7 / 9
2026-10-22	$-5.51	$3,600,000	7 / 9
2026-10-23	$-5.51	$3,600,000	7 / 9
2026-10-24	$-5.51	$3,600,000	7 / 9

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	10	0	0
2026-06-01	10	0	0
2026-07-01	10	0	0
2026-08-01	10	0	0
2026-09-01	10	0	0
2026-10-01	10	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Manage cash burn and operating expenses amid clinical developmentPublished status: Broken
Initiate registrational study of CRB-701 in 2L OPSCC by summer 2026Qualitative condition

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-76.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Corbus Pharmaceuticals Holdings Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not a business with established earnings. Its multi-year view depends on advancing CRB-701 and CRB-913, while the current thesis is on watch after weak financial performance and an earnings miss.

What's priced into Corbus Pharmaceuticals Holdings Inc

The valuation model has low confidence and points to a premium versus peers, driven by the possibility that its pipeline creates future value. That premium leaves expectations tied to clinical progress, while the evidence does not show revenue from the programs; the snapshot reports no valuation fragility flags.

What the fundamentals likely do

Near term, losses and elevated miss risk remain important, and operating expenses rose as cash declined between March and June 2026. Management has met clinical milestones: TEMPO-1 dosed its first patient in September, and CRB-913 results supported moving toward Phase 2. Management expects cash to fund operations into 2028, but the evidence shows limited progress on financial discipline as spending expands.

What Corbus Pharmaceuticals Holdings Inc hinges on

Over the next few quarters, the thesis hinges on avoiding a guidance cut and showing that clinical progress can continue without worsening cash pressure. A weakening jobs trend could add pressure across cyclical and Healthcare names, while continued strong results from sector leaders such as VRTX, REGN, and MRNA could support sector sentiment. The main multi-year swing factor is whether the two programs advance toward meaningful clinical development.